Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
Primary:
To determine the maximum tolerated dose and schedule of decitabine when administered as
maintenance therapy after allogeneic hematopoietic stem cell transplantation (alloHSCT)
performed for AML or high-risk MDS.